Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Hereditary Prostate Cancer Testing in Practice

March 13th 2018

Improvements in Detecting and Treating Metastatic CRPC

March 13th 2018

Utilizing AR-Targeted Therapies in CRPC

March 13th 2018

Assessing Treatment Response in M0 CRPC

March 13th 2018

Other Emerging Combination Approaches in RCC

March 13th 2018

AR-Targeted Therapies in CRPC

March 13th 2018

Treatment Goals in M0 CRPC

March 13th 2018

CRPC: Goals of Imaging for the Detection of Metastasis

March 13th 2018

Guidelines for Early Detection of Metastasis in CRPC

March 13th 2018

Treatment Challenges in Nonmetastatic CRPC

March 13th 2018

Detecting Newly Diagnosed Metastatic Prostate Cancer

March 13th 2018

Sequencing Therapy With ADT Combinations

March 13th 2018

Newly Diagnosed Metastatic Prostate Cancer Treatment

March 13th 2018

Risk Stratification in Nonmetastatic Prostate Cancer

March 13th 2018

Challenges Associated With ADT for Prostate Cancer

March 13th 2018

Considerations for Initiating ADT in Prostate Cancer

March 13th 2018

Apalutamide Added to NCCN Prostate Cancer Guidelines

March 12th 2018

The NCCN now lists apalutamide (Erleada) as a category 1 recommendation for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Gomella Discusses Precision Medicine in Prostate Cancer

March 9th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the role of precision medicine in prostate cancer.

2018 Ushers in New Era of Prostate Cancer Treatment

March 9th 2018

Edwin M. Posadas, MD, discusses the evolution of prostate cancer therapy, including the earlier use of advanced-stage agents and the potential for immunotherapy in the field.

Dr. Castle on Staging Modalities for Men With High-Risk Prostate Cancer

March 8th 2018

Erik P. Castle, MD, professor of urology, Mayo Clinic, discusses traditional imaging modalities and newer counterparts that are used to detect prostate cancer.